您当前的位置: > 详细浏览

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

摘要:BackgroundThe COVID-19 cases increased very fast in the last two months. The mortality among critically ill patients, especially the elder ones, was relatively high. Considering that most of the dead patients were caused by severe inflammation response, it is very urgent to develop effective therapeutic agents and strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown very good capability to modulate immune response and repair the injured tissue with good safety. Case PresentationHere, we reported the treatment process and clinical outcome of a 65-year-old female critically ill COVID-19 patient infected with 2019-nCoV (now called SARS-CoV-2). The significant clinical outcome and well tolerance was observed by the adoptive transfer of allogenic hUCMSCs.ConclusionsOur results suggested that the adoptive transfer therapy of hUCMSCs might be an ideal choice to be used or combined with other immune modulating agents to treat the critically ill COVID-19 patients.

版本历史

[V1] 2020-02-27 19:03:42 ChinaXiv:202002.00084V1 下载全文
点击下载全文
同行评议状态
待评议
许可声明
metrics指标
  • 点击量51095
  • 下载量8617
评论
分享
邀请专家评阅